[Cell Stem Cell] Researchers developed a drug-inducible phase-separation CAR system utilizing FDA-approved fulvestrant and an engineered estrogen receptor α mutant as the drug-inducible phase-separation module.

[Clinical Cancer Research] Scientists evaluated the safety, expansion kinetics, and preliminary efficacy of non-armored, nanobody-derived GCC-targeted CAR-T cells in patients with heavily pretreated, metastatic colorectal cancer.

[Cancer Research] The authors identified an innate-adaptive circuit in which toll-like receptor (TLR) 9-activated B cells augment CD8⁺ T cell fitness and antitumor activity through CD2-dependent costimulation.

[Journal for Immunotherapy of Cancer] Controllable Sleeping Beauty mutagenesis using DiSBey mice provides a novel platform for functional screening of genes that improve T cell phenotypes important for their use as therapies. Researchers highlighted a dose-dependent role of BACH2 in enhancing the function of engineered T cells under conditions of chronic antigenic stimulation.

[HemaSphere] Investigators conducted a multicenter retrospective study of patients registered in DESCAR-T who received standard-of-care CD19 CAR T cell therapy for relapsed or refractory B-cell non-Hodgkin lymphoma or B cell acute lymphoblastic leukemia and fulfilled ASTCT criteria for immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS).

[Biochemical Pharmacology] The expression of LILRB3 and LILRB4 was analyzed in monocytic acute myeloid leukemia (AML) patient samples, leukemic stem cell-enriched populations, and AML cell lines, revealing frequent co-expression and suggesting that a dual-targeting approach may provide enhanced therapeutic benefit.

[Scientific Reports] Researchers engineered MSLN-CAR-T cells with a PD1/IL15Rβ switch receptor to convert PD1/PDL1 inhibitory signals into IL15-mediated STAT5 activation, enhancing T cell function.

[Clinical and Experimental Dermatology] Scientists reported a 60-year-old woman with a 49-year history of severe, treatment-refractory plaque psoriasis who developed complete and sustained disease clearance following autologous CD19-directed chimeric antigen receptor (CAR) T cell therapy for follicular lymphoma.

[PloS One] CAR-T cells expressing interleukin-7 and CC chemokine ligand 19 were generated to achieve potent antitumor efficacy through the recruitment and proliferation of CAR-T cells and endogenous immune cells.

[Trends in Pharmacological Sciences] Scientists provided a decision framework that matches engineering strategies to cell types and drug properties, yielding baseline-qualified engineered cells.

[Molecular Therapy] The authors provide a decision framework that matches engineering strategies to cell types and drug properties, yielding baseline-qualified engineered cells.

[Journal of Translational Medicine] Investigators reviewed the biomechanical principles governing CAR-T antitumour responses and highlight how extracellular matrix rigidity, shear forces, and other mechanical cues shape CAR-T performance.